Day: July 30, 2020

Financial Highlights:Significant third quarter reduction in debt of $104.9 millionStrong third quarter operating cash flow exceeded $57.0 million; YTD exceeded prior year by $34.2 millionMemorialization segment reports higher sales for third fiscal quarter and YTDThird quarter GAAP EPS of $0.07; Non-GAAP adjusted EPS of $0.80PITTSBURGH, July 30, 2020 (GLOBE NEWSWIRE) — Matthews International Corporation (NASDAQ GSM: MATW) today announced financial results for its third quarter of fiscal 2020 and nine months ended June 30, 2020.In discussing the results for the Company’s fiscal 2020 third quarter, Joseph C. Bartolacci, President and Chief Executive Officer, stated:“I am very pleased with the performance of our overall business during these challenging times.  The relative stability of our consolidated results reflects the diversity...

NEW YORK, July 30, 2020 (GLOBE NEWSWIRE) — Fortress Transportation and Infrastructure Investors LLC (NYSE:FTAI) (the “Company” or “FTAI”) today reported financial results for the second quarter 2020. The Company’s consolidated comparative financial statements and key performance measures are attached as an exhibit to this press release.Financial OverviewFor the second quarter of 2020, total FAD was $47.3 million. This amount includes $82.1 million from our aviation leasing portfolio, offset by $(6.7) million from our infrastructure business and $(28.1) million from corporate and other.Second Quarter 2020 DividendsOn July 30, 2020, the Company’s Board of Directors (the “Board”) declared a cash dividend on its common shares of $0.33 per share for the quarter ended June 30, 2020, payable on August 31, 2020 to the holders of record...

DALLAS, July 30, 2020 (GLOBE NEWSWIRE) — Builders FirstSource, Inc. (Nasdaq:  BLDR) today reported its results for the second quarter ending June 30, 2020.Second Quarter 2020 Highlights:Net sales for the quarter increased by 2.2% compared to the prior year period– Core organic sales declined 2.1%, excluding acquisitions and commodity impacts– Acquisitions contributed net sales growth of 2.5%– Estimated sales volume, which includes core organic and acquisitions, grew by 0.4%– Commodity inflation increased sales by 1.8%Adjusted EBITDA increased 11.2% to a record $162 million, or 8.3% of net sales driven by disciplined cost managementNet income of $78.9 million, or $0.67 per diluted share, and adjusted net income of $79.2 million, or $0.67 per diluted shareStrong quarter-end balance sheet with a net debt to...

SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) — Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function, today announced that Histogen’s financial results for the second quarter ended June 30, 2020 will be released after the close of market on Thursday, August 13, 2020.About Histogen Inc.Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s...

Two U.S. FDA approvals in second quarter 2020Second quarter 2020 total revenue of $61.7 million and Crysvita revenue in Ultragenyx territories of $32.4 millionMaintains full year 2020 guidance based on global COVID-19 impact to dateNOVATO, Calif., July 30, 2020 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today reported its financial results for the quarter ended June 30, 2020 and maintained its full year 2020 financial guidance for Crysvita in Ultragenyx territories.“In the second quarter we made significant progress expanding the commercial reach of Crysvita and Mepsevii despite the COVID environment. We also expanded our commercial portfolio with two FDA approvals...

RICHMOND, Va., July 30, 2020 (GLOBE NEWSWIRE) — Kinsale Capital Group, Inc. (NASDAQ:KNSL) reported net income of $30.3 million, $1.33 per diluted share, for the second quarter of 2020 compared to $13.8 million, $0.63 per diluted share, for the second quarter of 2019. Net income was $35.3 million, $1.56 per diluted share, for the first half of 2020 compared to $32.5 million, $1.49 per diluted share, for the first half of 2019.Net operating earnings(1) were $19.1 million, $0.84 per diluted share, for the second quarter of 2020 compared to $12.4 million, $0.57 per diluted share, for the second quarter of 2019. Net operating earnings(1) were $36.4 million, $1.60 per diluted share, for the first half of 2020 compared to $26.3 million, $1.21 per diluted share, for the first half of 2019.Highlights for the second quarter and first half...

Provides Update on CPI-006 Phase 1 COVID-19 StudyConference Call Today at 4:30 p.m. ET / 1:30 p.m. PTBURLINGAME, Calif., July 30, 2020 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today provided a business update and announced financial results for the second quarter ended June 30, 2020.“In the second quarter, we advanced each of our three clinical oncology programs, highlighted by the presentation of new data at ASCO on the identification of a refined biomarker that enriches for responding patients with renal cell cancer treated with our lead candidate, ciforadenant,” said Richard A. Miller, M.D.,  president and chief executive officer of Corvus. “Based on this data, we are planning to meet with the U.S. Food & Drug Administration (FDA) to discuss the initiation...

BOSTON, July 30, 2020 (GLOBE NEWSWIRE) — Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will participate in a fireside chat presentation at the virtual William Blair Biotech Focus Conference 2020 on Thursday, August 6, at 2 p.m. EDT.The live webcast of the presentation will be accessible from the Media & Investors page of Albireo’s website, ir.albireopharma.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will be available for replay in the Events & Presentations section of the Media & Investors page of Albireo’s website for at least...

PITTSBURGH, July 30, 2020 (GLOBE NEWSWIRE) — NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense oligonucleotide (ASO) therapies using its scalable PATrOL™ platform to address genetic diseases, announced today that Dietrich Stephan, Chief Executive Officer of NeuBase, will participate in a virtual fireside chat at the BTIG Virtual Biotechnology Conference 2020, being held on August 10 – 11.About NeuBase TherapeuticsNeuBase Therapeutics, Inc. is developing the next generation of gene silencing therapies with its flexible, highly specific synthetic antisense oligonucleotides. The proprietary NeuBase peptide-nucleic acid (PNA) antisense oligonucleotide (PATrOL™) platform allows for the rapid development of targeted drugs, increasing the treatment opportunities...